Focus on embryonal malignancies

Cancer Cell

Volumn 2, Issue 6, 2002, Pages 447-450

  Maris, John M ^a,b   Denny, Christopher T ^c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MONOCLONAL ANTIBODY;

ARTICLE; CANCER IMMUNOTHERAPY; CELL SURFACE; CHROMOSOME REARRANGEMENT; GENE INACTIVATION; GENE LOCUS; GENETIC SUSCEPTIBILITY; GERM LINE; HEPATOBLASTOMA; HUMAN; NEPHROBLASTOMA; NEUROBLASTOMA; PREDICTION; PRIORITY JOURNAL; RETINOBLASTOMA; SOMATIC MUTATION; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE; ADULT; CELL TRANSFORMATION; CHILD; CHROMOSOME ABERRATION; GENE THERAPY; GENETIC PREDISPOSITION; GENETICS; IMMUNOTHERAPY; NEOPLASM; PRENATAL DEVELOPMENT; REVIEW;

ADULT; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHROMOSOME ABERRATIONS; GENE THERAPY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOTHERAPY; NEOPLASMS, GERM CELL AND EMBRYONAL;

EID: 0346644386     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00206-4     Document Type: Review

References (23)

1. Chen, D., Gallie, B.L., and Squire, J.A. (2001). Minimal regions of chromosomal imbalance in retinoblastoma detected by comparative genomic hybridization. Cancer Genet. Cytogenet. 129, 57-63.
2. Evans, A.E., Kisselbach, K.D., Yamashiro, D.J., Ikegaki, N., Camoratto, A.M., Dionne, C.A., and Brodeur, G.M. (1999). The anti-tumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin. Cancer Res. 5, 3594-3602.
3. Franks, L.M., Bollen, A., Seeger, R.C., Stram, D.O., and Matthay, K.K. (1997). Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer 79, 2028-2035.
4. Giardiello, F.M., Petersen, G.M., Brensinger, J.D., Luce, M.C., Cayouette, M.C., Bacon, J., Booker, S.V., and Hamilton, S.R. (1996). Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. Gut 39, 867-869.
5. Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70.
6. Huff, V., Amos, C.I., Douglass, E.C., Fisher, R., Geiser, C.F., Krill, C.E., Li, F.P., Strong, L.C., and McDonald, J.M. (1997). Evidence for genetic heterogeneity in familial Wilms' tumor. Cancer Res. 57, 1859-1862.
7. Keshelava, N., Zuo, J.J., Chen, P., Waidyaratne, S.N., Luna, M.C., Gomer, C.J., Triche, T.J., and Reynolds, C.P. (2001). Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 61, 6185-6193.
8. Kim, E., Moore, J., Huang, J., Soffer, S., Manley, C.A., O'Toole, K., Middlesworth, W., Stolar, C.J., Kandel, J.J., and Yamashiro, D.J. (2001). All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. J. Pediatr. Surg. 36, 287-290.
9. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D.J., Bohlen, P., and Kerbel, R.S. (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15-24.
10. Knudson, A.G., Jr. (1971). Mutation and cancer: Statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA. 68, 820-823.
11. Koch, A., Denkhaus, D., Albrecht, S., Leuschner, I., von Schweinitz, D., and Pietsch, T. (1999). Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the β-catenin gene. Cancer Res. 59, 269-273.
12. Koesters, R., Ridder, R., Kopp-Schneider, A., Betts, D., Adams, V., Niggli, F., Briner, J., and von Knebel Doeberitz, M. (1999). Mutational activation of the β-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res. 59, 3880-3882.
13. Maris, J.M., and Brodeur, G.M. (2001). Genetics of neuroblastoma. In Molecular Genetics of Cancer, J.K. Cowell, ed. (Oxford: BIOS), pp. 335-361.
14. Maris, J., Weiss, M., Mosse, Y., Hii, G., Guo, C., White, P., Hogarty, M., Mirensky, T., Brodeur, G., Rebbeck, T., et al. (2002). Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Res. 62, 6651-6658.
15. Matthay, K.K., DeSantes, K., Hasegawa, B., Huberty, J., Hattner, R.S., Ablin, A., Reynolds, C.P., Seeger, R.C., Weinberg, V.K., and Price, D. (1998). Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J. Clin. Oncol. 16, 229-236.
16. Matthay, K.K., Villablanca, J.G., Seeger, R.C., Stram, D.O., Harris, R.E., Ramsay, N.K., Swift, P., Shimada, H., Black, C.T., Brodeur, G.M., et al. (1999). Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341, 1165-1173.
17. Meitar, D., Crawford, S.E., Rademaker, A.W., and Cohn, S.L. (1996). Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J. Clin. Oncol. 14, 405-414.
18. Ozkaynak, M.F., Sondel, P.M., Krailo, M.D., Gan, J., Javorsky, B., Reisfeld, R.A., Matthay, K.K., Reaman, G.H., and Seeger, R.C. (2000). Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J. Clin. Oncol. 18, 4077-4085.
19. Reynolds, C. P. (2000). Differentiating agents in pediatric malignancies: retinoids in neuroblastoma. Curr. Oncol. Rep. 2, 511-518.
20. Ries, L.A.G., Smith, M.A., Gurney, J.G., Linet, M., Tamra, T., Young, J.L., and Bunin, G.R. (1999). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. (Bethesda, MD: NIH Pub. No. 99-4649)
21. Ross, J.A., and Swensen, A.R. (2000). Prenatal epidemiology of pediatric tumors. Curr. Oncol. Rep. 2, 234-241.
22. Teitz, T., Wei, T., Valentine, M.B., Vanin, E.F., Grenet, J., Valentine, V.A., Behm, F.G., Look, A.T., Lahti, J.M., and Kidd, V.J. (2000). Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 6, 529-535.
23. Weiss, W.A., Aldape, K., Mohapatra, G., Feuerstein, B.G., and Bishop, J.M. (1997). Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16, 2985-2995.